NM_000546.6(TP53):c.451C>A (p.Pro151Thr) AND Li-Fraumeni syndrome

Germline classification:: Pathogenic (1 submission)
Last evaluated:: Apr 18, 2025
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV000691152.13

Allele description [Variation Report for NM_000546.6(TP53):c.451C>A (p.Pro151Thr)]

NM_000546.6(TP53):c.451C>A (p.Pro151Thr)

Gene:

TP53:tumor protein p53 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

17p13.1

Genomic location:

Preferred name:

NM_000546.6(TP53):c.451C>A (p.Pro151Thr)

HGVS:

NC_000017.11:g.7675161G>T
NG_017013.2:g.17390C>A
NM_000546.6:c.451C>AMANE SELECT
NM_001126112.3:c.451C>A
NM_001126113.3:c.451C>A
NM_001126114.3:c.451C>A
NM_001126115.2:c.55C>A
NM_001126116.2:c.55C>A
NM_001126117.2:c.55C>A
NM_001126118.2:c.334C>A
NM_001276695.3:c.334C>A
NM_001276696.3:c.334C>A
NM_001276697.3:c.-27C>A
NM_001276698.3:c.-27C>A
NM_001276699.3:c.-27C>A
NM_001276760.3:c.334C>A
NM_001276761.3:c.334C>A
NP_000537.3:p.Pro151Thr
NP_000537.3:p.Pro151Thr
NP_001119584.1:p.Pro151Thr
NP_001119585.1:p.Pro151Thr
NP_001119586.1:p.Pro151Thr
NP_001119587.1:p.Pro19Thr
NP_001119588.1:p.Pro19Thr
NP_001119589.1:p.Pro19Thr
NP_001119590.1:p.Pro112Thr
NP_001263624.1:p.Pro112Thr
NP_001263625.1:p.Pro112Thr
NP_001263689.1:p.Pro112Thr
NP_001263690.1:p.Pro112Thr
LRG_321t1:c.451C>A
LRG_321:g.17390C>A
LRG_321p1:p.Pro151Thr
NC_000017.10:g.7578479G>T
NM_000546.4:c.451C>A
NM_000546.5:c.451C>A
P04637:p.Pro151Thr
p.P151T

Protein change:

P112T; PRO151THR

Links:

UniProtKB: P04637#VAR_005896; OMIM: 191170.0025; dbSNP: rs28934874

Molecular consequence:

NM_001276697.3:c.-27C>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001276698.3:c.-27C>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001276699.3:c.-27C>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_000546.6:c.451C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001126112.3:c.451C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001126113.3:c.451C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001126114.3:c.451C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001126115.2:c.55C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001126116.2:c.55C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001126117.2:c.55C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001126118.2:c.334C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001276695.3:c.334C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001276696.3:c.334C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001276760.3:c.334C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001276761.3:c.334C>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:: Li-Fraumeni syndrome (LFS)
Synonyms:: Sarcoma family syndrome of Li and Fraumeni
Identifiers:: MONDO: MONDO:0018875; MedGen: C0085390; OMIM: PS151623

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV000818896	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Pathogenic (Apr 18, 2025)	germline	clinical testing	PubMed (13) [See all records that cite these PMIDs] 11479205, 25503501, 29979965, 30224644, 7881428, 10713666, 12826609, 16861262, 20128691, 20522432, 21343334, 23625637, 28492532

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV000818896

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Pathogenic
(Apr 18, 2025)

germline

clinical testing

PubMed (13)
[See all records that cite these PMIDs]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.

Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomäki K, Nevanlinna H.

Cancer Res. 2001 Aug 1;61(15):5718-22.

PubMed [citation]

PMID:: 11479205

Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.

Maxwell KN, Wubbenhorst B, D'Andrea K, Garman B, Long JM, Powers J, Rathbun K, Stopfer JE, Zhu J, Bradbury AR, Simon MS, DeMichele A, Domchek SM, Nathanson KL.

Genet Med. 2015 Aug;17(8):630-8. doi: 10.1038/gim.2014.176. Epub 2014 Dec 11.

PubMed [citation]

PMID:: 25503501
PMCID:: PMC4465412

See all PubMed Citations (13)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV000818896.8

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (13)

Description

This sequence change replaces proline, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 151 of the TP53 protein (p.Pro151Thr). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with early-onset breast cancer and TP53-related disease (PMID: 11479205, 25503501). ClinVar contains an entry for this variant (Variation ID: 12369). Invitae Evidence Modeling incorporating data from in vitro experimental studies (PMID: 12826609, 29979965, 30224644) indicates that this missense variant is expected to disrupt TP53 function with a positive predictive value of 97.5%. Experimental studies have shown that this missense change affects TP53 function (PMID: 12826609, 29979965, 30224644). This variant disrupts the p.Pro151 amino acid residue in TP53. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 7881428, 10713666, 12826609, 16861262, 20128691, 20522432, 21343334, 23625637). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Apr 12, 2026

ClinVar

Relating variation to medicine